Morgan Stanley just doubled its price target for CRISPR Therapeutics to $60, a bold move as the stock has lagged the market this year. Their approved drug Casgevy, treating sickle cell and beta thalassemia, just got expanded to include kids as young as two — a major sales catalyst. Despite high costs and complex delivery, the real excitement is in the pipeline: CTX310, expected to deliver big data by year-end, could offer a one-time cure for high cholesterol — a game-changer. Already the only gene-editing company with an approved therapy, CRISPR’s future looks bright. But Morgan Stanley’s “hold” rating and cautious analyst views remind investors this isn’t a sure thing — do your homework, because other teams are spotting even better long-term plays.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
